<DOC>
	<DOC>NCT02136927</DOC>
	<brief_summary>Pharmacokinetic, bioequivalence study</brief_summary>
	<brief_title>Bioavailability Study of SPARC1210 and Reference1210 in Subjects With Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>The subject has given written, informed consent and is available for the entire study. Histologically or cytologically confirmed diagnosis of breast cancer; Locally recurrent or metastatic breast cancer for which taxanebased therapy is a rational treatment option; Age 18 years or more Known hypersensitivity to both the study drugs or its excipients (Cholesteryl sulfate, Caprylic acid, Polyvinylpyrrolidone, Ethanol or Polyethylene glycol); Presence of clinically evident active CNS metastases, including leptomeningial involvement, requiring steroid or radiation therapy; Preexisting clinically significant peripheral neuropathy (Grade 2 or higher according to CTCAE, Version 4.0); Any other severe concurrent disease which in the judgment of the investigator would make the subject inappropriate for entry into this study</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>